News Author: Christopher Palmer Publish date: October 8, 2019
This is the first treatment approved to help patients with erythropoietic protoporphyria increase their exposure to light.
News Author: Christopher Palmer Publish date: October 8, 2019
The researchers implemented five interventions and went from fully immunizing slightly more than half to almost every infant in the neonatal ICU.
News Author: Christopher Palmer Publish date: October 7, 2019
Results from 52 weeks showed significantly greater improvement among patients taking secukinumab for nonradiographic disease, compared with placebo...
News Author: Christopher Palmer Publish date: October 4, 2019
Benralizumab is already approved as add-on maintenance for this form of asthma, but not for other eosinophilic conditions or for acute bronchospasm...
News Author: Christopher Palmer Publish date: September 27, 2019
AbobotulinumtoxinA (Dysport) is now approved for upper-limb spasticity in both children 2 years and older (excluding those with cerebral palsy) and...
News Author: Christopher Palmer Publish date: September 26, 2019
This marks the drug’s second approved indication this year and its seventh overall.
News Author: Christopher Palmer Publish date: September 25, 2019
The affected lots were recalled because NDMA, a nitrosamine impurity and probable carcinogen, was detected at levels above those set by the FDA.
News Author: Christopher Palmer Publish date: September 24, 2019
The association was stronger among families with lower socioeconomic status than among those with middle or high socioeconomic status.
News Author: Christopher Palmer Publish date: September 20, 2019
The association was particularly strong with externalizing behavioral problems.
News Author: Christopher Palmer Publish date: September 19, 2019
Dental care was the only prevention strategy of eight examined that was linked to decreased recurrence.
News Author: Christopher Palmer Publish date: September 17, 2019
The sirolimus-eluting balloon delivers the drug for below-the-knee peripheral artery disease without the need for...
News Author: Christopher Palmer Publish date: September 13, 2019
The biologic has been approved for patients aged 6 years and older in the European Union since August 2018.
News Author: Christopher Palmer Publish date: September 13, 2019
Improvements in number of complete spontaneous bowel movements and abdominal pain were seen as early as week 1 of the phase 3 trials.
News Author: Christopher Palmer Publish date: September 7, 2019
Interstitial lung disease affects half of scleroderma patients in the United States, and until now there was no treatment.
News Author: Christopher Palmer Publish date: August 29, 2019
The connection may be related to insulin resistance.
